Agenda

MASTERCLASS WORKSHOPS (NEW)
Tuesday, September 17, 2019
CONFERENCE DAY 1
Wednesday, September 18, 2019
CONFERENCE DAY 2
Thursday, September 19, 2019

Registration and Networking Breakfast

Developing Your Competitive Expertise: Late-Lifecyle Management & Competitive Uncertainty

Dr. Baljit Singh, Managing Director and Partner, INOVIS, Pharmaceuticals and Life Sciences Division (formerly Director, Integrated Insights, Novartis)
Dr. Satish Kumar, Head, CI Strategies, Generics & Biosimilars, INOVIS (formerly Sanofi-Genzyme)
Dr. Harshal Kubavat, Head, Strategic Consulting, Life Sciences, INOVIS (formerly Brand Manager, Roche)

This workshop session (with breakouts), will give participants first-hand insights from combined 30+ years of experience dealing with uncertainty and helping Big Pharma optimize their late-life cycle strategies – i.e. enabling companies to protect and optimize their assets.

PART-A: Threat-Analysis as a Strategy to Manage Uncertainty

Using an INOVIS proprietary strategy-gaming exercise, participants will be provided with a business case study and suggested frameworks to perform threat analysis, in order to:

• Apply new analytical frameworks to a pharma-like business case study in a learning environment
• Evaluate the importance of comprehensive & robust threat assessments and the impact these can have on strategic decision making (commercial readiness, development programs, BD opportunities, forecasting, scenario planning, mitigation plans, etc.)
• Acquire ideas and initiatives that can be rapidly integrated into ongoing CI Practice

PART-B: Gx/Biosimilar CI Assessments and Strategic Framework

Leveraging a specific Gx / biosimilar example, the second part of this workshop will address and highlight best practices when implementing follow-up activities related to identified actions during a strategic gaming exercise, this interactive workshop session will specifically enable you to:

• Get to the core issues at hand and the appropriate CI solution
• Identify appropriate analytical activities
• Set up a best-in-industry Gx/biosimilar RI and CI tracking program
• Understand Gx / Biosimilar product development and entry strategies
• Identify potential actions to optimize launches

Networking Lunch

Best Practices to Create/Write Effective and Impactful CI Reports and Presentations

Dave Alderman, President Molekule Consulting
Dr. Daniel Pascheles, CEO, Molekule Consulting

An “art” and “science” exists when considering clear, concise and actionable competitive strategy report writing in the biopharmaceutical space.

Many biopharma CI reports disseminated by the Agency are overly verbose, high-level and lack the substantive actionability required for internal usage – facilitating a seamless cascade to management & leadership.

Today’s workshop will translate classical stylistic business writing techniques including those of Strunk and White to the 21st-century biopharmaceutical CI and Strategy world.

In this workshop, we will facilitate two (2) breakouts during which “raw intelligence learnings” will be synthesized and translated into actionable CI deliverables using PowerPoint writing skills and infographic design techniques.

This Workshop is facilitated by David Alderman, President of Molekule Consulting, a global competitive intelligence and strategy consultancy dedicated to the life sciences and biopharmaceutical verticals. David has deep experience from early-development to late-lifecycle management and beyond within biopharma across the competitive landscape among myriad therapy areas, players and subject matters. David is a Subject Matter Expert on the biopharmaceutical vertical; with a particular focus on competition within branded biopharma, small molecule generics and biosimilars.

Networking Break and Refreshments

A Framework for Success in Digital Healthcare Solutions: Choosing the Right Approach in the Right Context

Alec Lee, Practice Leader, DuckerFrontier
Stephen Majors, Director, Healthcare Practice, DuckerFrontier

As the line blurs between pharma companies and tech companies, pharma companies are racing to find success in digital solutions.

But there is little agreement on a definition for digital solutions and rarely a focused strategy to make them profitable. This session will present a framework for conceptualizing digital solutions and thinking through the market opportunity and competitive landscape for a range of digital solutions.

Registration & Networking Breakfast in Exhibition Hall

Chairpersons’ Opening Remarks

Presented by Bayer and Merck & Co.

Keynote: Connected Health at the Speed of Life

Reaching and engaging the connected patient: Data first, Speed up & Provide Assistance in a mobile world

Presented by Google

Keynote: Quintessential Agency Industry Partnership – How to Make it Work!

We will role-play what a good and a more difficult agency / client relationship looks like. The goal of our “performance” is to provide the audience with an entertaining learning experience.

Topics we will cover:
• Scoping a project and preparing the brief
• Choosing an agency
• Interacting with the agency during the project
• Delivery of the project results

The audience can expect to be able to participate actively in the “conversation” and contribute to the program

Presented by Chiesi and Molekule Consulting

Refresh and Connect in Exhibition Hall

Keynote: Executive Level Discussions: Strategic CI Boardroom

A panel of CI Leaders from the following companies:

Presented by Abbott Laboratories, Bayer Consumer Health, BioMarin, Boehringer Ingelheim, Eli Lilly and Company, Johnson & Johnson, Merck, and Novartis

“Ask the Experts” Interactive Breakout Groups

(Explore and capture the power of participants’ Insights and experiences and exploration of these topics in this fun and informal environment in small groups.)
BREAKOUT 1
Decoding Signals of Potential Disruptive Forces

Presented by Abbvie

BREAKOUT 2
Digital/Data

Presented by Novartis

BREAKOUT 3
Due Diligence Support

A substantial amount of Due Diligence goes into licensing and acquisition deals in pharma.

CI professionals play a key role in preparing for successful deals. This discussion will focus on how CI can support a large array of DD activities beyond the preparation of a competitive landscape. DD projects provide extraordinary opportunity for CI professionals to deliver outstanding value to the business by supporting and leading hosts of activities within the DD process. This discussion is intended to help raise awareness of the many ways CI can deliver value for DD projects.

Presented by Eagle Pharmaceuticals

BREAKOUT 4
Information and Insights Monet Style – Who Frames the Whole Painting?

In this session, we’ll discuss all of the various types of disparate information available to a pharma company, including CI.

In some Monet paintings, there are lots of dots of color, but only until you back-up that you see the whole picture. The question we’ll dig into is, who is putting the painting in a frame to create a cohesive picture or do we just have multiple painters with information, but no cohesiveness to it all.

Presented by Merck

BREAKOUT 5
Is Primary CI Collection Becoming Obsolete? With the Advent of Counter-CI Measures by the Industry, How Are CI Collectors Remaining Ahead of the Curve Without Compromising Ethics?

Presented by BioMarin

Networking Luncheon

Dessert/Coffee and Capabilities Mini Presentations (Optional) in Exhibition Hall

Idea Labs: Gain New Perspectives

SESSION ONE

Early Stage CI and Product Pipeline

Learn how early stage assets can benefit from CI support.

During the early stages of product development, CI tends to be undervalued due to the high risk of failure which means low or zero budget. However, including CI in the early stages of development can help optimise clinical programs to be more competitive on the market. For example, learning from the failures of your competitors.

This talk will address the following questions and provide some ideas on how to plan and execute successful CI projects during the early stages of drug development.

• Why is it important to understand the market and its competitors prior to launch?
• When to begin planning pre‐launch CI projects?
• What types of information can be gathered?

Presented by Lifescience Dynamics

SESSION TWO

Lessons from Inside Novartis, Roche, and Atacana - 5 Questions You Need to Ask to Maximize Your Success and Significantly Increase the Value of Your Competitive Intelligence

Many CI professionals fail to understand that the perceived value of their CI work is the basis for their career success.

Still, others fail to realize that they must translate the importance of their insights into long-term gains for the stakeholders in the stakeholders’ perception.

One of pharma’s most successful CI professionals reveals 5 questions you must ask at the beginning of each project to ensure:

1. A dramatic return on investment for your CI efforts
2. Be recognized for the impact you are creating in your organization
3. Increase your resources and get your next promotion

In this presentation, Salvador Carlucci clearly demonstrates how CI professionals can educate their stakeholders on how to determine the real value of competitive intelligence and how to capture that value to propel their career. Filled with inspirational stories and practical advice, make sure not to miss this presentation.

Presented by Atacana Group

SESSION THREE

Building CI Functions for Competitive Advantage

• How do strategic and competitive intelligence need to adapt to drive value in a more agile world?

• What are the opportunities for the CI function in such a dynamic market? How can these opportunities be realized?
• What can CI functions and managers do to ensure their intelligence continues to drive value, growth, and strategy?

Presented by Deallus

Think Tanks: Learning Environment

SESSION ONE

Top 10 Challenges in CI – How to Face them Head-On

There is need for a “shake-up” in competitive intelligence.

Old-school and business-as-usual methodologies and deliverables will not cut it in an ever-changing business and technological environment that demands greater efficiencies in collection and analysis, and greater demands on ROI effectiveness of CI deliverables. As the American-Canadian writer William Gibson once said, “The future is already here – it’s just not very evenly distributed.” Prescient has surveyed CI stakeholders and has captured a list of the top challenges faced by CI teams. We will discuss the industry “norms” and the advent of budding new and futuristic solutions that will shake up the way we think of CI.

Presented by Prescient Healthcare Group

SESSION TWO

From Strategic to Predictive Intelligence – the Future is History

How the Life Science industry is using Artificial Intelligence?

How the new tools can be used to facilitate our roles within Strategic Intelligence?
How can we integrate secondary, primary and artificial intelligence for the benefit of our internal stakeholders?

Presented by GlobalReach BI

SESSION THREE

Planning for New Pharmaceutical Markets

Recent developments in the holistic pharmaceuticals market presage significant changes in the overall power dynamics.

Acquisitions such as the CVS/Aetna merger and the Walgreens/Express Scripts group purchasing alliance are indications of new trends in the market. These trends have the potential to significantly change how decisions are made in the market. This session will present a set of future scenarios that depict the market based on extension of the trends. Using interactive tools, participants will model out strategies that pharmaceutical companies will need to implement to thrive in the environment.

Key Take-aways:
1. New thinking about how the traditional pharmaceutical market will change by 2030
2. Expanded awareness of potential impacts from alliances between health insurance carriers, pharmacies, and pharmacy benefits managers
3. Exploration into ways the government can intervene in the market based on different scenarios
4. Broad strategic options for pharmaceutical companies

Presented by Fletcher/CSI

SESSION FOUR

10 Lessons from a CI Life

After 17 years at Pfizer and 25 years as a CI professional in both industry and consultancy, Marjorie Norman has seen a lot of changes.

However, some basic truths still hold strong. This session will address Marjorie’s experience – the good, the bad and the ugly – in developing and maintaining a best-in-class CI program.

Presented by Cambridge Healthcare Research

Evolving Technology and Skills: Learn and Engage

SESSION ONE

Leveraging Technology to Drive Competitive Intelligence: Hype vs. Reality

Technologies such as Natural language processing (NLP) and artificial intelligence (AI) are augmenting strategic competitive intelligence teams, executive teams, boards, regulators and investors.

In this session, we’ll go beyond the hype and show the real value that AI and NLP can add to your competitive intelligence processes. Answering questions, such as how are competitors talking about you, your products, and your market? Or, how does your peer’s business guidance compare to yours?
You’ll learn:
• How these technologies can directly answer the most critical questions posed by Competitive Intelligence analysts
• How applied AI can save Competitive Intelligence teams hundreds of hours of work each month
• Where these technologies can provide competitive insights unreachable with the legacy approach to research

Presented by Sentieo

SESSION TWO

A Big Data Approach to Emerging Trends: A Use-Case in Oncology

There are different ways to surface innovative and emerging biotech companies and the assets they produce.

Some are opportunistic, namely conferences, arranged meetings, and internal strategic focus areas. Other methods deploy bottom-up approaches looking at company performance measures, such as clinical success and financial info. Lastly, some strategists prefer the top-down approach, namely analyzing trends across a wide variety of medical conditions to look for an emerging molecular target, modality or new treatments. This allows for a better understanding of the formation and dynamics of the trend, and how much potential it holds (if any) to become effective, and ubiquitous, and expandable. In this presentation, Dr. Madar will focus on recent technology trends, emphasize and characterize one of them, and provide examples for leading entities in this field.

Presented by Signals Analytics

SESSION THREE

Pharma & Value-Based Care: The Evolution of Contracting and Business Models

‘Value-based care’ models have taken hold in the provider setting – particularly primary care – and now represent roughly half of US payer reimbursements.

Combined with rising public scrutiny on drug prices, this trend will increasingly drive pharma suppliers toward value-based contracting. This session will define ‘value-based contracting,’ provide examples of different types of arrangements, present obstacles to adoption, and explain how pharma companies can play a more proactive role in the evolution toward ‘value-based care.’

Presented by DuckerFrontier

Refuel & Rejuvenate in Exhibition Hall

Leadership Insight: Case Studies

SESSION ONE

How to Be Successful as a 1-Person CI Team

Session aims to identify challenges a 1-Person CI Team faces and, ultimately, provide some potential solutions to ensure its success.

Challenges include: defining your role, understanding the expertise you bring to the table, amplifying your voice, winning buy-in, measuring your success, knowing when and how to expand.

Presented by Pfizer

SESSION TWO

Case study in using CI for Pre-launch Targeting vs Post Launch

Venturing into a new therapeutic area has its challenges especially for new products.

In the case we will look at a product launch and how initial targeting used best available data and intelligence. We will explore what happened post launch and discuss how soon should you change your strategy if the results are not what was expected. Do you need to have a wealth of data to make a change?

Presented by Amneal Pharmaceuticals

SESSION THREE

Adapting Predictive Analytics in an Organization to Gain Competitive Edge

Presented by Promius Pharma

SESSION FOUR

Benchmarking to Get a Seat at the Table

Presentation highlighting examples of benchmarking activities and projects when done effectively can grant CI professionals access to decision makers and forums for influencing strategy.

Presented by Eli Lilly and Company

Engagement: High Level Debate and Discussion

SESSION ONE

Strategy, BD and Market Access

Presented by Amicus Therapeutics, GlaxoSmithKline, Ionis Pharmaceuticals, Sanofi Pasteur, and Sobi

SESSION TWO

Insights into New Product Planning and Decision Making

Presented by Alnylam Pharmaceuticals, Daiichi Sankyo, Ipsen Biopharmaceuticals, and Taiho Oncology

SESSION THREE

Pharma and Diagnostics

Presented by Align Strategy, The Dunn Group, and Roche Diagnostics

Drink, Eat & Be Merry! Casino Night Cocktail Reception & Networking

Registration & Networking Breakfast in Exhibition Hall

Case Histories: Sharing Experiences and Expertise

SESSION ONE

Competitive Intelligence Software Overview: How’s It Being Used Today and How Will It Impact the CI Function Going Forward?

Presented by Abbott Laboratories

SESSION TWO

Payer Research Planning in the Era of Real World Evidence: Who Knows More About Your Product?

Presented by Summit Therapeutics

SESSION THREE

Launch Analytics: Importance in Defining Launch Strategy

The availability of granular HCP and patient level data in pharmaceutical industry helps companies take a deep dive and gain comprehensive understanding of market.

This understanding helps target the right product in order gain market share and the right customer (HCP) in order to increase promotional impact. The combination of these and other steps together helps define a winning launch strategy.

Presented by Lupin Pharmaceuticals

SESSION FOUR

The AI Impact: How AI-Enabled Technology is Changing Pharma and Healthcare

Technology has and continues to fundamentally change the way in which pharmaceutical and healthcare industries monitor, analyze, and disseminate information.

Artificial intelligence, while just a piece of this technological equation, has the power to accelerate strategic partnerships and growth by providing visibility into the market for competitive intelligence professionals.

For those in the industry, knowledge of regulatory activities, FDA drug approvals, and the shifting M&A landscape is critical to competitive intelligence. Join AlphaSense for an informative session about AI’s future impact on pharma and how it is currently transforming the role of the competitive intelligence analyst.

Learn how AI can…
– Quickly access and monitor important competitive information to enable focused research and deliver meaningful insights
– Fuel analysis and build confidence in seeing the bigger picture
– Empower teams to make smarter decisions by leveraging the latest data and news

Presented by AlphaSense

Idea Labs: Gain New Perspectives

SESSION ONE

Social Media Monitoring and Analysis of Medical Conferences

Medical conference and tradeshow monitoring provides excellent opportunities for primary research and capture of data as soon as it is shared with the public.

The increased use of social media to share opinions regarding emerging data from conferences and tradeshows by patients, researchers, health care providers, and key thought leaders provides a new opportunity for pharmaceutical companies to improve understanding of perception related to developing and existing therapeutic approaches. While social media platforms provide basic search capabilities, subscription-based services provide the ability to analyze all social media activity from an event while offering powerful insights into user communities, influence of specific individuals, and the most widely discussed presentations and events from an event. During this presentation, we’ll share outputs from this type of analysis and share thoughts about how these activities fit into a comprehensive conference monitoring approach.

Presented by Proactive Worldwide

SESSION TWO

Ensuring Full Value from CI by Full Integration into the Strategic Planning Process

The Osprey team of strategic consultants will share experiences and perspectives on the role of the CI function in strategic planning, how to ensure CI is used well and appropriately and will provide examples of best practice from the Osprey Health Consulting wide experience of strategic planning across therapy areas.

Presented by Osprey Health Consulting

SESSION THREE

Key Issues in Managed Care and Specialty Pharmacy: Impact on the Industry

Presented by Healthcare Intelligence and Analytics

SESSION FOUR

Transformative Innovation - How ‘Big Pharma’ is Seeking to Replicate the Creativity and Nimbleness of ‘Start-up Pharma’?

Ambition horizons and investment in transformative growth

“Design Thinking” and its application across the whole organisation
Digital transformation and the rise of the Chief Digital Officer

Presented by Dig Worldwide

Refresh and Connect in Exhibition Hall

Best Practices and Insights

SESSION ONE

Looking at Competitive Intelligence through a Statistical Lens

Competitive Intelligence is most often practiced as an Art and a Science.

In this presentation we discuss how to view CI through a statistical/probabilistic lens. The discussion is motivated through the Let’s Make a Deal game show to understand how to leverage prior knowledge about an event and factor in new information through CI. The discussion will demystify Markov Chain Monte Carlo simulation methods and show how these methods can be used to help generate insights into a probability model of product launch timings. Combining launch timings with drug feature sets ( safety, efficacy and dosing ) we will show how to gain qualitative insight into NBRx. This discussion will not be a forecasting seminar and no advanced degrees are required. The objective of the talk is to provide talking points so that you can discuss with your Advanced Analytics team on how to model product launches based on competitive intelligence information and understand potential uptake of products.

Presented by Roche

SESSION TWO

Ensuring Appropriate Stakeholder Buy-in to Support Intelligence Programs

As intelligence professionals, we often have difficulty securing adequate budget for what we believe are critical projects for our assets.

Oftentimes, our department goals and objectives are difficult to achieve without budget to support external, specialized agency support. Attend this session to understand key strategies to develop and achieve wins with your functional and brand team in advance of budget time. Key short-term wins will enable you to capture stakeholder buy-in and budget for future projects.

Presented by Ionis Pharmaceuticals

SESSION THREE

Digital Therapeutics – A New ‘Pill’ar in Big Pharma

Major deals, investments, and partnerships between pharma companies and burgeoning digital therapeutic companies have become regular headline news.

What does big pharma need to know and what is being missed? How will prescription digital therapeutics (PDTs) be reimbursed? How will medical policies and drug formularies change as PDTs enter the market? As physicians, patients, and payers embrace technology to drive better treatment outcomes at lower costs, pharma companies are getting aligned to optimize their competitive positions. This session will provide the needed insight.

Presented by Click Therapeutics

SESSION FOUR

Transitioning from Vendor to Client Side

CI professionals from Merck will discuss the lessons they've learned working both on the vendor and client side.

They’ll share their thoughts on:
• How vendors view clients and how they define a successful relationship
• How clients view vendors and why they decide to work with one over another
• How to measure success.
• Do’s and don’ts from both sides of the table
• Better ways to partner

Presented by Merck

“Ask the Experts” Interactive Breakout Groups

(Explore and capture the power of participants’ Insights and experiences and exploration of these topics in this fun and informal environment in small groups.)
BREAKOUT 1
Decoding Signals of Potential Disruptive Forces

Presented by Abbvie

BREAKOUT 2
Digital/Data

Presented by Novartis

BREAKOUT 3
Due Diligence Support

A substantial amount of Due Diligence goes into licensing and acquisition deals in pharma.

CI professionals play a key role in preparing for successful deals. This discussion will focus on how CI can support a large array of DD activities beyond the preparation of a competitive landscape. DD projects provide extraordinary opportunity for CI professionals to deliver outstanding value to the business by supporting and leading hosts of activities within the DD process. This discussion is intended to help raise awareness of the many ways CI can deliver value for DD projects.

Presented by Eagle Pharmaceuticals

BREAKOUT 4
Information and Insights Monet Style – Who Frames the Whole Painting?

In this session, we’ll discuss all of the various types of disparate information available to a pharma company, including CI.

In some Monet paintings, there are lots of dots of color, but only until you back-up that you see the whole picture. The question we’ll dig into is, who is putting the painting in a frame to create a cohesive picture or do we just have multiple painters with information, but no cohesiveness to it all.

Presented by Merck

BREAKOUT 5
AAV Gene Therapy - Are These Therapies Ready for the Prime Time? Best Practices on GT CI

Presented by BioMarin

Networking Luncheon

Dessert/Coffee and Capabilities Mini Presentations (Optional) in Exhibition Hall

Announcement of Raffle Prize Winners

Keynote: The Pricing/Access Box

Drug companies face an odd business environment: they sell to fewer, larger buyers drugs for fewer, sicker patients.

A handful of corporate behemoths, most created very recently, control huge portions, sometimes majority shares, of the insurance, distribution, and retail and pharmacy businesses. These vertically aligned giants will influence – often control — 80% of prescriptions. Their pricing power is increasing almost exponentially.

Meanwhile, in the still relatively free-market world of the US, governments are becoming increasingly agitated – with the Federal government threatening, among other things, European-style price indexing while the States are introducing a raft of initiatives, including laws, like California’s, requiring drug firms to justify price increases.

The biopharma industry’s response has largely been to back as rapidly as it can into what it perceives is the pricing immunity of rare diseases: new approvals in these categories constitute more than half of the industry’s output. Companies are thus drastically improving the lives of a very small number of people and paying for the pricing flexibility with often substantially increased patient costs and, as an industry, a shrinking medical importance to society as a whole.

This talk will discuss these issues and their business implications, as well as possible ways forward for the industry and in particular, the new capabilities successful companies will require.

Presented by Real Endpoints

Competitive Intelligence “PRIME”: Can Our Industry Keep Up?

By exploring the rapid evolutions taking place inside and outside of the pharmaceutical industry, we will consider whether our profession has adapted at a similar pace and what more can be done to elevate our role.

With seemingly endless “on-demand”, “tailored”, “agile” and “VUCA-driven” solutions touching our professional and personal lives every day, this session seeks to address what best practices, ideas and solutions can be leveraged into our working practices to generate further impact to our teams, stakeholders and wider organizations. Delivered by two leading CI industry experts, the INOVIS team looks forward to an engaging, dynamic and hopefully provocative audience participation-driven approach, which will leave you with a fresh outlook on the future of CI in the Pharmaceutical industry and how to optimize your personal impact on decision making!

Presented by INOVIS

Power Panel: Review and Discussion of the Most Controversial and Important Topics During the Two Days

A panel of CI Leaders from the following companies:

Presented by Abbott Laboratories, Bayer Consumer Health, BioMarin, Boehringer Ingelheim, Eli Lilly and Company, Johnson & Johnson, Merck, and Novartis

Conference Concludes